Spider angioma

WikiDoc Resources for Spider angioma
Articles
Most recent articles on Spider angioma Most cited articles on Spider angioma Review articles on Spider angioma Articles on Spider angioma in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Spider angioma Images of Spider angioma Photos of Spider angioma Podcasts & MP3s on Spider angioma Videos on Spider angioma
Evidence Based Medicine
Cochrane Collaboration on Spider angioma Bandolier on Spider angioma TRIP on Spider angioma
Clinical Trials
Ongoing Trials on Spider angioma at Clinical Trials.gov Trial results on Spider angioma Clinical Trials on Spider angioma at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Spider angioma NICE Guidance on Spider angioma NHS PRODIGY Guidance FDA on Spider angioma CDC on Spider angioma
Books
Books on Spider angioma
News
Spider angioma in the news Be alerted to news on Spider angioma News trends on Spider angioma
Commentary
Blogs on Spider angioma
Definitions
Definitions of Spider angioma
Patient Resources / Community
Patient resources on Spider angioma Discussion groups on Spider angioma Patient Handouts on Spider angioma Directions to Hospitals Treating Spider angioma Risk calculators and risk factors for Spider angioma
Healthcare Provider Resources
Symptoms of Spider angioma Causes & Risk Factors for Spider angioma Diagnostic studies for Spider angioma Treatment of Spider angioma
Continuing Medical Education (CME)
CME Programs on Spider angioma
International
Spider angioma en Espanol Spider angioma en Francais
Business
Spider angioma in the Marketplace Patents on Spider angioma
Experimental / Informatics
List of terms related to Spider angioma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Historical Perspective

• [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
• In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
• In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

• [Disease name] may be classified according to [classification method] into [number] subtypes/groups:

• [group1]
• [group2]
• [group3]

• Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

• The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
• The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
• On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
• On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Causes

Disease name] may be caused by [cause1], [cause2], or [cause3].

OR

Common causes of [disease] include [cause1], [cause2], and [cause3].

OR

The most common cause of [disease name] is [cause 1]. Less common causes of [disease name] include [cause 2], [cause 3], and [cause 4].

OR

The cause of [disease name] has not been identified. To review risk factors for the development of [disease name], click here.

Differentiating [disease name] from other Diseases

• [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

• [Differential dx1]
• [Differential dx2]
• [Differential dx3]

Epidemiology and Demographics

• The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.

• In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Patients of all age groups may develop [disease name].

• [Disease name] is more commonly observed among patients aged [age range] years old.
• [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

• There is no documented study showing gender predilection for Spider Angioma in otherwise healthy population.
• However there is an increased incidence in pregnant women, which

Race

• There is no racial predilection for Spider Angiomas, but can have more visibility in light skinned people.

Risk Factors

• Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

• The majority of patients with [disease name] remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

• There is no diagnostic criteria for Spider angioma.

History and Symptoms

• Spider angioma, when not extensive, can be benign.
• When present extensively it could be due to an underlying cause.
• About 33% of the patients with advanced liver cirrhosis have spider angioma.
• Alcoholism and higher bilirubin levels were proven to have correlation for development of Spider angiomas.
• Young females h

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical Examination

• Patients with [disease name] usually appear [general appearance].
• Spider angiomas are usually present on face, chest and arms in the distribution of Superior Vena Cava. But unusual presentations with Palpebra, Pluera and subpleura, esophaghus ,and gastrointestinal tracts have been reported.
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• Laboratory work up for hepatic etiology (Liver function tests, Viral markers), pregnancy (urine pregnancy test), hyperestrogenic etiology (Estrogen and FSH levels) and thyrotoxicosis (T3,T4, and TSH) should be done.

Electrocardiogram

• There are no ECG findings associated with Spider angiomas.

X-ray

• There are no x-ray findings associated with Spider angiomas.

Echocardiography or Ultrasound

• There are no echocardiography/ultrasound findings associated with Spider angiomas as such.
• Ultrasound has a high positive predictive value in identifying the underlying liver cirrhosis.
• Ultrasound may be useful in identifying underlying ovarian tumors.

CT scan

• There are no CT scan findings associated with Spider angiomas.
• CT scan is the most sensitive imaging modality for identifying the underlying liver cirrhosis.
• Ct scan can reveal underlying ovarian tumors.

MRI

• There are no MRI findings associated with Spider angiomas.

Other Imaging Findings

• There are no other imaging findings associated with Spider angiomas.

Other Diagnostic Studies

• Biopsy may be helpful in the diagnosis of Spider angioma when the presentation isn't classical. Findings diagnostic of spider angioma include Cutaneous arterial net, Central spider arteriole, Subepidermal ampulla , Star shaped arrangement of efferent spider vessels, and Capillaries.

Treatment

Medical Therapy

• There is no treatment for [disease name]; the mainstay of therapy is supportive care.

• The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action 1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for [disease name].
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
• [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

• There are no primary preventive measures available for [disease name].

• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].